28.00p
+1.82%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cambridge Cognition Holdings
Its shares trade on LSE under the ticker COG.L. It has been listed since 18 April 2013. In the fiscal year to 31 December 2025, it reported revenue of £9.4m and a net loss of £1.7m. At that date it held total assets of £11.3m and shareholders' equity of £3.0m.
Cambridge Cognition Holdings Plc is a neuroscience digital health company, which engages in the development of digital health products to better understand, detect, and treat conditions affecting brain health. The firm's segments include Pharmaceutical Clinical Trials, Academic Research and Healthcare Technology. The Pharmaceutical Clinical Trials segment includes products and services for use in regulated pharmaceutical clinical trials. The Academic Research segment includes cognitive test products for researchers working in a non-regulated environment, typically in academia. The Healthcare Technology segment includes medical software for use in healthcare delivery settings. The firm is a provider of validated touchscreen cognitive assessments for clinical trials. The firm's product, CANTAB Mobile is a Class II medical device, used to identify patients exhibiting the early signs of Alzheimer's disease. The company also offers Cantab Insight for dementia assessment in secondary care.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 18 Apr 2013
- Employees
- 71
- Website
- cambridgecognition.com ↗
Leadership
Pay as last reported
- Dr. Steven PowellNon-Executive Chairman of the Board, since 2015£45,000
- Mr. Robert BakerChief Operating Officer, Acting Joint Managing Directors, since 2025
- Ms. Francesca CormackCambridge Cognitions Chief Scientist
- Mr. Alex Livingstone-LearmonthChief Commercial Officer, Acting Joint Managing Directors
- Mr. Simon McKeatingCompany Secretary
- Mr. Richard BungayNon-Executive Independent Director£30,000
- Mr. Stuart GallNon-Executive Independent Director£28,000
- Mr. Jonathan KempsterNon-Executive Independent Director
- Ms. Debra LeevesNon-Executive Independent Director£30,000
- Mr. Nick RodgersNon-Executive Independent Director£28,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cambridge Cognition Holdings PLC has established a strong reputation in the field of cognitive assessment and digital health solutions. The company's expertise in developing innovative technology and software for cognitive testing sets it apart from competitors. Its products are widely recognized and trusted by healthcare professionals and researchers.
- The company has a diverse customer base, both in terms of geographies and sectors. This broad market presence provides Cambridge Cognition Holdings PLC with stability and opportunities for growth. Furthermore, the company's partnerships with renowned academic institutions and pharmaceutical companies enhance its credibility and open doors to collaborative research and development.
Weaknesses
- One of the weaknesses of Cambridge Cognition Holdings PLC is its dependency on key clients and contracts. If the company loses a significant client or fails to renew a major contract, it may experience a decline in revenue. Additionally, the company may face challenges in effectively scaling its operations to meet increasing demand for its solutions.
- Cambridge Cognition Holdings PLC operates in a rapidly evolving market, which means that it needs to continuously invest in research and development to stay ahead. This constant need for innovation creates a financial burden and poses a risk if the company fails to keep pace with technological advancements.
Opportunities
- An opportunity for Cambridge Cognition Holdings PLC lies in the growing demand for digital health solutions and cognitive assessment tools. The global healthcare industry is increasingly recognizing the importance of early detection and management of cognitive disorders, creating a favorable market environment for the company's products.
- Expansion into new geographical markets can also be a significant opportunity for the company. By targeting regions with underutilized cognitive assessment technologies, Cambridge Cognition Holdings PLC can tap into untapped markets and increase its customer base.
Threats
- One of the threats faced by Cambridge Cognition Holdings PLC is the presence of strong competitors in the market. Other companies offering cognitive assessment solutions and digital health platforms may have similar or even superior offerings, which can impact the company's market share and profitability.
- Moreover, regulatory challenges and changes in healthcare policies can pose a threat to the operations of Cambridge Cognition Holdings PLC. Compliance with evolving regulations and maintaining high data security standards is crucial for the company's success and reputation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.